Skip to main content
SpringerLink
Log in

Klinische Bedeutung und Behandlungsperspektiven

Erhöhte Lp(a)-Konzentrationen

  • Fortbildung_Lipidologie
  • Published:
CardioVasc Aims and scope

Erhöhte Lp(a)-Konzentrationen sind kausal mit einem erhöhten kardiovaskulären Risiko assoziiert. Es steht weder eine medikamentöse noch eine sonstige Behandlung zur Verfügung, die selektiv die Lp(a)-Konzentration verringert. Randomisierte, kontrollierte Studien mit der Fragestellung, ob die selektive Reduktion von erhöhten Lp(a)-Konzentrationen in der Lage ist, kardiovaskuläre Endpunkte positiv zu beeinflussen, fehlen und sind dringend erforderlich.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904–910

    Article  CAS  PubMed  Google Scholar 

  2. Nielsen LB, Gronholdt ML, Schroeder TV et al. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol. 1997;17:905–911

    Article  CAS  PubMed  Google Scholar 

  3. Bennet A, Di Angelantonio E, Erqou S et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008;168:598–608

    Article  CAS  PubMed  Google Scholar 

  4. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102:1082–1085

    Article  CAS  PubMed  Google Scholar 

  5. Craig WY, Neveux LM, Palomaki GE et al. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem. 1998;44:2301–2306

    CAS  PubMed  Google Scholar 

  6. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–2853

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–423

    Article  CAS  PubMed  Google Scholar 

  8. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117:176–184

    Article  CAS  PubMed  Google Scholar 

  9. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–2339

    Article  CAS  PubMed  Google Scholar 

  10. Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–2528

    Article  CAS  PubMed  Google Scholar 

  11. Gouni-Berthold I, Berthold HK. Lipoprotein(a): current perspectives. Curr Vasc Pharmacol. 2011;9:682–692

    Article  CAS  PubMed  Google Scholar 

  12. Berthold HK, Gouni-Berthold I. Hyperlipoproteinemia(a): clinical significance and treatment options. Atheroscler Suppl. 2013;14:1–5

    Article  CAS  PubMed  Google Scholar 

  13. Seed M, O'Connor B, Perombelon N et al. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis. 1993;101:61–68

    Article  CAS  PubMed  Google Scholar 

  14. Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267

    Article  PubMed  Google Scholar 

  15. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:279-1291

  16. Gouni-Berthold I, Berthold HK. Antisense oligonucleotides for the treatment of dyslipidemia. Curr Pharm Des. 2011;17:950–960

    Article  CAS  PubMed  Google Scholar 

  17. Cannon CP, Shah S, Dansky HM et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–2415

    Article  CAS  PubMed  Google Scholar 

  18. Ladenson PW, Kristensen JD, Ridgway EC et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010;362:906–916

    Article  CAS  PubMed  Google Scholar 

  19. Berthold HK, Laudes M, Krone W, Gouni-Berthold I. Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans. PLoS One. 2011;6:e24719

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chennamsetty I, Claudel T, Kostner KM et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest. 2011;121:3724–3734

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tsimikas S, Viney NJ, Hughes SG et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386:1472–1483

    Article  CAS  PubMed  Google Scholar 

  22. Benjannet S, Rhainds D, Esselmani R et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptorand LDL cholesterol. J Biol Chem. 2004;279:48865–48875

    Article  CAS  PubMed  Google Scholar 

  23. Gouni-Berthold I, Berthold HK. PCSK9 antibodies for the treatment of hypercholesterlemia. Nutrients. 2014;6:5517–5533

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sabatine MS, Giugliano RP, Wiviott SD et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–1509

    Article  CAS  PubMed  Google Scholar 

  25. Raal FJ, Stein EA, Dufour R et al. PCSK9 inhibition with evolocumab (AMG 145) in herozygous familial hypercholesterlemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331–340

    Article  CAS  PubMed  Google Scholar 

  26. Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–1499

    Article  CAS  PubMed  Google Scholar 

  27. Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198:247–255

    Article  CAS  PubMed  Google Scholar 

  28. Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis. 2006;189:31–38

    Article  CAS  PubMed  Google Scholar 

  29. Julius U, Frind A, Tselmin S et al. Comparison of different LDL apheresis methods. Expert Rev Cardiovasc Ther. 2008;6:629–639

    Article  CAS  PubMed  Google Scholar 

  30. Myers GL, Christenson RH, Cushman M et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem. 2009;55: 378–384

    CAS  PubMed  Google Scholar 

  31. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28:2375–2414

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universität zu Köln, Poliklinik für Endokrinologie, Diabetologie und Präventivmedizin, Kerpener Str. 62, 50937, Köln, Deutschland

    Ioanna Gouni-Berthold

Authors
  1. Ioanna Gouni-Berthold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ioanna Gouni-Berthold.

Additional information

Interessenkonflikte

Prof. Gouni-Berthold hat Vortrags- und Beraterhonorare sowie Unterstützung für Bildungsaktivitäten von Amgen, Sanofi/Genzyme, Aegereon, und Astra-Zeneca erhalten. Sie war medizinische Leiterin einer Prüfgruppe für eine multizentrische Studie von IONIS Pharmaceuticals mit einem Antisense-Oligonucleotid gegen Apo-A sowie für Studien mit Alirocumab (Sanofi) und Evolocumab (AMGEN).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gouni-Berthold, I. Erhöhte Lp(a)-Konzentrationen. CV 16, 50–53 (2016). https://doi.org/10.1007/s15027-016-1033-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-016-1033-5

Search

Navigation